// App-Quantinova.ai

TPS2640 : A phase I trial of MK-2206 and hydroxychloroquine(HCQ) in solid tumors, melanoma, renal, and prostate cancer to examine the role of autophagy in tumorigenesis.

Researchers

Presenter

  • Amanda D. Kaveney

Principal Investigators

  • Janice M. Mehnert

  • Antoinette R. Tan

  • Robert S. DiPaola

  • Darlene Gibbon

  • Shari Adams

  • Jane Fischer

  • Pamela Scott

  • Christian Gable

  • Austin Doyle

  • Mark N. Stein

  • Joseph Aisner

  • Rebecca Anne Moss

Medical Centers

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • National Cancer Institute, Rockville, MDRutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJRutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Cancer Inst of New Jersey Robert Wood Johnson Univ Hosp, New Brunswick, NJ

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Rutgers Biomedical Health Sciences, Newark, NJ.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Solid malignancies

  • Prostate cancer

  • Melanoma

Biomarkers

  • 1A/1B-light chain 3

Drug/Treatment

  • Hydroxychloroquine

  • MK 2206

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01480154

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved